The Fort Worth Press - SMX Brings Identity to Cannabis and rPET Under FDA-Compliant Frameworks

USD -
AED 3.672499
AFN 63.000218
ALL 81.288631
AMD 374.006028
ANG 1.789884
AOA 917.999815
ARS 1374.796916
AUD 1.39804
AWG 1.8025
AZN 1.701218
BAM 1.665113
BBD 2.01512
BDT 122.759818
BGN 1.668102
BHD 0.377275
BIF 2975.105995
BMD 1
BND 1.273476
BOB 6.913109
BRL 4.972103
BSD 1.000451
BTN 93.790972
BWP 13.451617
BYN 2.814964
BYR 19600
BZD 2.012209
CAD 1.366565
CDF 2313.999771
CHF 0.781895
CLF 0.022674
CLP 892.37015
CNY 6.82165
CNH 6.82785
COP 3587.3
CRC 455.822507
CUC 1
CUP 26.5
CVE 93.876908
CZK 20.751028
DJF 178.157299
DKK 6.369515
DOP 60.208755
DZD 132.379122
EGP 51.988604
ERN 15
ETB 157.484803
EUR 0.85227
FJD 2.194496
FKP 0.740159
GBP 0.740655
GEL 2.690045
GGP 0.740159
GHS 11.075448
GIP 0.740159
GMD 73.502853
GNF 8781.085844
GTQ 7.646989
GYD 209.3344
HKD 7.831984
HNL 26.580678
HRK 6.419903
HTG 130.965962
HUF 311.528025
IDR 17199
ILS 3.00095
IMP 0.740159
INR 93.75325
IQD 1310.596128
IRR 1320999.99996
ISK 122.559701
JEP 0.740159
JMD 158.492044
JOD 0.708983
JPY 159.216012
KES 129.179789
KGS 87.427398
KHR 4004.835771
KMF 419.999715
KPW 899.990254
KRW 1478.359427
KWD 0.30819
KYD 0.833745
KZT 463.595498
LAK 22073.421989
LBP 89593.471709
LKR 317.917894
LRD 184.091335
LSL 16.446219
LTL 2.95274
LVL 0.60489
LYD 6.326571
MAD 9.238104
MDL 17.138041
MGA 4149.568356
MKD 52.526174
MMK 2099.66818
MNT 3578.517246
MOP 8.0708
MRU 39.939723
MUR 46.519756
MVR 15.459805
MWK 1734.492329
MXN 17.31875
MYR 3.952499
MZN 63.901353
NAD 16.446219
NGN 1348.72979
NIO 36.821672
NOK 9.29944
NPR 150.065555
NZD 1.693155
OMR 0.384483
PAB 1.000528
PEN 3.43825
PGK 4.400759
PHP 60.163499
PKR 278.910249
PLN 3.619405
PYG 6293.366934
QAR 3.647718
RON 4.341401
RSD 100.058034
RUB 75.017642
RWF 1461.969385
SAR 3.75032
SBD 8.038772
SCR 14.260087
SDG 599.999782
SEK 9.18375
SGD 1.273735
SHP 0.746601
SLE 24.593572
SLL 20969.496166
SOS 571.778849
SRD 37.472498
STD 20697.981008
STN 20.858697
SVC 8.754693
SYP 110.631499
SZL 16.439919
THB 32.205014
TJS 9.419537
TMT 3.505
TND 2.90915
TOP 2.40776
TRY 44.92475
TTD 6.78285
TWD 31.509502
TZS 2599.999967
UAH 43.897001
UGX 3706.888478
UYU 39.776259
UZS 12134.653533
VES 481.046775
VND 26322.5
VUV 117.946979
WST 2.711482
XAF 558.460897
XAG 0.012793
XAU 0.00021
XCD 2.70255
XCG 1.803113
XDR 0.694162
XOF 558.465651
XPF 101.534165
YER 238.625022
ZAR 16.46934
ZMK 9001.200483
ZMW 19.034038
ZWL 321.999592
  • AZN

    0.2750

    196.055

    +0.14%

  • GSK

    0.0250

    56.14

    +0.04%

  • CMSD

    0.0050

    23.045

    +0.02%

  • NGG

    2.1700

    86.44

    +2.51%

  • CMSC

    -0.0700

    22.66

    -0.31%

  • BCE

    0.1810

    24.091

    +0.75%

  • JRI

    0.0960

    13.146

    +0.73%

  • RYCEF

    -1.3100

    15.85

    -8.26%

  • RBGPF

    -13.5000

    69

    -19.57%

  • RIO

    2.3200

    100.05

    +2.32%

  • BTI

    0.9000

    55.75

    +1.61%

  • BP

    0.7349

    46.635

    +1.58%

  • VOD

    0.2150

    15.405

    +1.4%

  • RELX

    0.2050

    37.28

    +0.55%

  • BCC

    0.1100

    82.505

    +0.13%

SMX Brings Identity to Cannabis and rPET Under FDA-Compliant Frameworks
SMX Brings Identity to Cannabis and rPET Under FDA-Compliant Frameworks

SMX Brings Identity to Cannabis and rPET Under FDA-Compliant Frameworks

NEW YORK, NY / ACCESS Newswire / December 19, 2025 / Cannabis is entering a phase where identity matters more than narrative. As federal oversight takes shape, the industry is being pulled out of a patchwork of state systems and into a framework that resembles other regulated categories. In those environments, compliance is not about disclosure. It is about proof.

Text size:

That shift changes what it means to operate at scale.

Federal normalization does not immediately transform cannabis into a pharmaceutical, but it does move it closer to medical-grade expectations. Products that are ingested, absorbed, or used therapeutically are judged by how well their physical reality aligns with their records. Labels, declarations, and after-the-fact reporting are no longer sufficient. Regulators expect continuity between what a product is and what the system says it is.

This is where identity becomes infrastructure. Here's why it's vital to this conversation.

Cannabis Needs Verification, Not Visibility

Most cannabis compliance systems were built for speed and local reporting. They track activity, but they do not always verify integrity. Under light oversight, that distinction is tolerable. Under federal scrutiny, it becomes a liability.

Federal regulators expect records that hold up over time. They expect chain-of-custody continuity from origin through distribution. They expect discrepancies to be explainable without reconstruction. When systems rely on manual reconciliation or fragmented data, those expectations are difficult to meet.

SMX (NASDAQ:SMX) approaches this problem at the material level. Instead of relying solely on databases or documentation, its technology embeds identity directly into physical materials. That identity persists through transformation and movement, allowing records to reflect reality rather than attempt to approximate it.

For cannabis, that approach aligns naturally with the direction of federal oversight. When proof is embedded, compliance becomes continuous instead of episodic.

FDA-Compliant RPET Shows The Model Works

This same logic is already operating inside FDA-regulated markets.

SMX recently demonstrated its molecular marking technology in recycled PET plastics used for food-contact applications, operating within FDA Food Contact Substance regulations under 21 CFR. These rules govern some of the most tightly controlled materials in the supply chain. Any system that functions here must demonstrate stability, safety, and verifiable compliance.

In practice, molecular markers allow recycled material to carry permanent, invisible proof of origin, composition, and regulatory status, even in applications where contamination risk is tightly controlled. This enables recycled plastics to move into categories that were previously closed to them.

That matters for cannabis because the regulatory expectation is similar. When a product interacts with the human body, regulators care less about intent and more about verifiable control. Food-grade rPET provides a real-world demonstration that molecular identity can operate inside strict federal frameworks.

From Cannabis To Plastics, The Compliance Logic Is Shared

Cannabis and rPET are different markets, but they face the same regulatory logic. Both require traceability that survives transformation. Both demand proof that cannot be altered downstream. Both expose the weaknesses of systems built on declarations.

SMX's relevance is not tied to a single product category. It is tied to the need for persistent identity in regulated environments. Whether the material is plant-based or polymer-based, the requirement is the same. Physical goods must be able to prove what they are.

As cannabis moves toward federal standards, that requirement becomes unavoidable.

Identity Becomes The Foundation Of Scale

Markets are no longer rewarding speed alone. They are rewarding control.

SMX's ability to embed identity at the molecular level and to operate within FDA-compliant frameworks positions it at the intersection of regulation and scalability. Cannabis operators moving into federal oversight face the same decision that plastics manufacturers already confront. Patch legacy systems, or adopt infrastructure built for verification.

As oversight tightens, the difference becomes decisive.

Cannabis will not be filtered by enthusiasm or branding. It will be filtered by execution. The companies that can prove integrity across their supply chains will advance. Those who cannot will face compounding friction.

Identity is no longer a feature. It is the foundation.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

This information contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, estimates, forecasts, and assumptions regarding future events involving SMX (NASDAQ: SMX), its technologies, its partnership activities, and its development of molecular marking systems for recycled PET and other materials. Forward looking statements are not historical facts. They involve risks, uncertainties, and factors that may cause actual results to differ materially from those expressed or implied.

Forward looking statements in this editorial include, but are not limited to, expectations regarding the integration of SMX's molecular markers into U.S. recycling markets; the potential for FDA-compliant markers to enable recycled PET to enter food-grade and other regulated applications; the scalability of SMX solutions across diverse global supply chains; anticipated adoption of identity-based verification systems by manufacturers, recyclers, regulators, or brand owners; the potential economic impact of turning recycled plastics into tradeable or monetizable assets; the expected performance of SMX's Plastic Cycle Token or other digital verification instruments; and the belief that molecular-level authentication may influence pricing, compliance, sustainability reporting, or financial strategies used within the plastics sector.

These forward looking statements are also subject to assumptions regarding regulatory developments; market demand for authenticated recycled content; the pace of corporate adoption of traceability technology; global economic conditions; supply chain constraints; evolving environmental policies; and general industry behavior relating to sustainability commitments and recycling mandates. Risks include, but are not limited to, changes in FDA or international regulatory standards; technological challenges in large-scale deployment of molecular markers; competitive innovations from other companies; operational disruptions in recycling or plastics manufacturing; fluctuations in pricing for virgin or recycled plastics; and the broader economic conditions that influence capital investment and industrial activity.

Detailed risk factors are described in SMX's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on forward looking statements. These statements speak only as of the date of publication. SMX undertakes no obligation to update or revise forward looking statements to reflect subsequent events, changes in circumstances, or new information, except as required by applicable law.

EMAIL: [email protected]

SOURCE: SMX (Security Matters) Public Limited



View the original press release on ACCESS Newswire

S.Rocha--TFWP